FDA Brief

Warning letters Drugs

FDA warning letter to

Distributor RFR, LLC

High riskIssued Jan 9, 2023Posted Jan 10, 2023Center for Drug Evaluation and Research | CDER

FDA: Distributor RFR's SANGTER male energy supplement contained undeclared sildenafil, making it an unapproved, misbranded new drug.

What happened

FDA inspected Distributor RFR's facility in Doral, FL, on June 2-3, 7, 10, and 14, 2022, and took a sample and labeling of "SANGTER Natural Male Energy Supplement" during the inspection. FDA also reviewed the firm's website, www.sangter.com. Laboratory analysis found the undeclared active drug ingredient sildenafil (the active ingredient in the prescription drug Viagra), while the product was marketed as a dietary supplement with claims about erectile dysfunction and sexual performance.

What FDA found

  1. The product is a new drug sold without an FDA-approved drug application.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. Because it contains sildenafil, which was not sold as a food or supplement before Viagra was approved in 1998, the product cannot legally be a dietary supplement.

    Section 201(ff)(3)(B)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i)
  3. Its labeling does not give adequate directions for safe use, which is impossible for a prescription drug containing sildenafil.

    Section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1)
  4. The labeling is misleading because it does not reveal that the product contains sildenafil, a drug that can cause serious harm or interact dangerously with nitrates.

    Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  5. The labeling lacks adequate warnings to protect users from the risks of the undeclared drug ingredient.

    Section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2)
  6. Website claims about erectile dysfunction and libido show the product is intended to be used as a drug.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

FDA asks the company to write within fifteen working days describing the specific steps taken to correct the violations and prevent them from happening again, with supporting documents, or to explain why the products are not in violation. If corrections cannot be finished in that time, the company must state the reason and a completion date.

Who should pay attention

  • retailers and online sellers of male enhancement supplements
  • distributors and importers of supplement products
  • brands whose products share suppliers or ingredient sources with this firm

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk